Mechanism of Action:

Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro.

Drug Label Information | Brands:


Lincar-B®, Globe
Lincocin®, Pfizer Upjohn
Lincomycin, Gracure
Lincomycin, Swiss Parenterals (Pvt.) Ltd
Lincozed®, Zawadi Healthcare Ltd


Lincomycin is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial associated pseudomembranous colitis, the physician should consider the nature of the infection and the suitability of other alternatives.

Indicated surgical procedures should be performed in conjunction with antibacterial therapy.

The drug may be administered concomitantly with other antimicrobial agents when indicated.

Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Lincomycin and other antibacterial drugs, Lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.


This drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.


Gastrointestinal disorders

Diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort , anal pruritus

Skin and subcutaneous tissue disorders

Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis,dermatitis bullous, dermatitis exfoliative, erythema multiforme (see WARNINGS), rash, urticaria, pruritus

Infections and infestations

Vaginal infection, pseudomembranous colitis, Clostridium difficile colitis (see Vaginal infection, pseudomembranous colitis, Clostridium diffi cile colitis

Blood and lymphatic system disorders

Pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, thrombocytopenic purpura

Immune system disorders

Anaphylactic reaction , angioedema, serum sickness

Hepatobiliary disorders

Jaundice, liver function test abnormal, transaminases increased

Renal and urinary disorders

Renal impairment, oliguria, proteinuria, azotemia

Cardiac disorders

Cardio-respiratory arrest

Vascular disorders

Hypotension , thrombophlebitis1

Ear and labyrinth disorders

Vertigo, tinnitus

Neurologic disorders

Headache, dizziness, somnolence

General disorders and administration site conditions

Injection site abscess sterile , injection site induration , injection site pain , injection site irritation


  • lincomycin increases effects of Neuromascular Junction Blockers by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
  • Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
  • lincomycin, rimabotulinumtoxin B. Either increases effects of the other by pharmacodynamic synergism.Closely monitor for increased neuromuscular blockade.

Prescription Category:
DDA Schedule:
Dosage Forms:
Routes of Administration:
Protein Binding:
Elimination Half life:
Drug Indentifiers:

References/ Citation:

Prescription Category:
DDA Schedule:
Dosage Forms:
Routes of Administration:
Protein Binding:
Elimination Half life:
Drug Indentifiers:

References/ Citation: